Biotech · Public company · Thousand Oaks, CA, US

Latigo Biotherapeutics, Inc.

Ticker LTGO · SEC CIK 0002056611

Track this companyFree. Adds Latigo Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials30 recruiting or active

Pipeline programs10From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline10

Active Comparator: HB/APAPPhase 2 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
Experimental: LTG-001 High DosePhase 2 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
Experimental: LTG-001 Low DosePhase 2 · Acute PainClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 High DosePhase 2 · Acute Pain, PostoperativeClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 Low DosePhase 2 · Acute Pain, PostoperativeClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 Mid DosePhase 2 · Acute Pain, PostoperativeClinicalTrials.gov · fetched Nov 12, 2026
SuzetriginePhase 2 · Acute Pain, PostoperativeClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 Formulation A Prototype 1Phase 1 · Pain ManagementClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 Formulation B Prototype 2Phase 1 · Pain ManagementClinicalTrials.gov · fetched Nov 12, 2026
LTG-001 SDDPhase 1 · Pain ManagementClinicalTrials.gov · fetched Nov 12, 2026

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy ParticipantsPHASE1 · COMPLETED · started Oct 6, 2025ClinicalTrials.gov NCT07341152 · fetched Nov 12, 2026
An Efficacy and Safety Study of LTG-001 Following AbdominoplastyPHASE2 · COMPLETED · started Jul 24, 2025ClinicalTrials.gov NCT07102459 · fetched Nov 12, 2026
This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsPHASE2 · COMPLETED · started Dec 19, 2024ClinicalTrials.gov NCT06774625 · fetched Nov 12, 2026